Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Conditions
Brief summary
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
Interventions
DRUGDocetaxel injection
75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
DRUGTriptorelin Pamoate for Injectable Suspension
15mg every 12 weeks
5 mg oral low dose prednisone, once daily
Sponsors
Hongqian Guo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be ≥ 18 and ≤75 years of age. * All patients must have a histologically or cytologically diagnosis of prostate cancer and must be eligible for radical prostatectomy. * All patients must undergo thorough tumor staging and meet one of the following criteria: 1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ T3, 2. Gleason score of primary tumor ≥ 8, 3.prostate specific antigen (PSA) ≥20 ng/ml. 3. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1. 4. Patients must have adequate hematologic function, within 28 days prior to registration as evidenced by: white blood cell (WBC) ≥ 4.0 × 109 /L, platelets≥ 100 × 109 / L, hemoglobin ≥ 9 g / dL, and international normalized ratio (INR) \< 1.5. 5. Patients must have adequate hepatic function, within 28 days prior to registration, as evidenced by: total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN),and SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN. 6. Patients must have adequate renal function, within 28 days prior toregistration, as evidenced by serum creatinine ≤2×ULN * Patients must participate voluntarily and sign an informed consent form(ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.
Exclusion criteria
* Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible. * Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor \< T3, Gleason score of primary tumor \< 8, and prostate specific antigen (PSA) \<20 ng/ml. * Patients with clinical or radiological evidence of extra-regional lymph node metastases or bone metastases or visceral metastases are not eligible. * Patients who have previously received androgen deprivation therapy (medical or surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy are not eligible. * Patients with severe or uncontrolled concurrent infections are not eligible. * Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration. * Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection. * Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled. * Patients with mental illness, mental disability or inability to give informed consent are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response Rate | up to 8 months | The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy. |
| pCR or MRD rate | up to 8 months | The proportion of patients with pCR or MRD. Pathologic complete response (pCR): defined as no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy. Minimal Residual Disease (MRD): defined as residual tumors with maximum diameter of 3 mm or less after radical prostatectomy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Positive Surgical Margins | up to 8 months | The proportion of subjects with positive surgical margins after radical prostatectomy. |
| Rate of Complete Serum Remission | up to 8 months | The proportion of subjects whose PSA is less than or equal to 0.2 ng/ml after 6 months of treatment. |
| Operative time (min) | 12 month | The operative time(min) of radical prostatectomy. |
| Estimated blood loss (ml) | 12 month | Estimated blood loss (ml) during the process of radical prostatectomy. |
| Hospital length of stay (day) | 12 month | The hospitalization time, recorded in day. |
| Drainage duration (day) | 12 month | Length of drainage duration, recorded in day. |
| Imaging Response Rate | up to 8 months | The proportion of subjects whose primary tumor is in complete remission on imaging or residual tumor's maximum diameter is less than 0.5cm. |
| Recovery time of urinary continence (day) | 12 month | The recovery time of urinary continence (day) after radical prostatectomy, defined as 0 pad/day. |
| biochemical progression-free survival (bPFS) | 3 years | Biochemical progression was defined as two consecutive rising PSA values that were above 0.2ng/ml at least one month apart, or starting adjuvant therapy after surgery including radiotherapy, ADT or anti-androgen therapy. The time for bPFS was measured from randomization to biochemical progression or death from any cause. |
| metastasis-free survival (MFS) | 5 years | Time from date of randomization to date of evidence of systemic disease on bone scan or cross-sectional imaging. |
| Serum complete response rate | after 6 month neoadjuvant therapy and before surgery | Serum complete response rate, defined as the proportion of participants with PSA ≤ 0.1 ng/mL after 6-month neoadjuvant therapy. |
| Rate of extracapsular extension | 12 month | The proportion of patients with extracapsular extension on pathologic specimens after neoadjuvant therapy. |
| Rate of positive lymph node | 12 month | The proportion of patients with positive lymph node on pathologic specimens after neoadjuvant therapy. |
| Incidence of complications (%) | 12 month | The proportion of subjects who suffer from major complications. |
| Rate of Stage Degradation | up to 8 months | Clinical or pathological stage degradation after neoadjuvant therapy |
Countries
China
Outcome results
None listed